Canadian scientists at the Lawson Health Research Institute have made a groundbreaking discovery in cancer treatment. Researchers found that a therapy derived from human waste, known as Faecal Microbiota Transplant (FMT), could significantly improve recovery in patients with lung and skin cancer.
How Faecal Microbiota Treatment Works
FMT uses waste from healthy donors, which is then frozen, dried, and converted into easy-to-swallow capsules using advanced technology. These capsules introduce beneficial bacteria into the patient’s digestive system, creating a stronger immune response.
Unlike traditional treatments, FMT does not attack cancer cells directly. Instead, it boosts the body’s natural defences, making conventional cancer drugs more effective. Experts explain that a healthier gut microbiome can improve immune system performance, which is crucial in fighting cancer.
Clinical Trial Results
Phase 2 clinical trials produced encouraging results:
Improved Effectiveness: FMT capsules alone improved treatment response by 40–45% compared to standard immunotherapy drugs.
Enhanced Drug Efficiency: When combined with traditional treatments, the success rate increased to 80%, with cancer cells either reduced or controlled in 79% of patients.
These findings suggest that FMT could become an important complement to conventional cancer therapies, particularly for patients who have not responded well to standard treatments.
Experts See a New Direction in Oncology
Oncology specialists believe this breakthrough represents a shift toward more precise and personalised biological treatments. By harnessing the power of gut bacteria, researchers hope to enhance cancer recovery while reducing side effects commonly seen with aggressive chemotherapy and immunotherapy.
The Lawson Health team continues to explore the full potential of FMT capsules and plans to expand trials to cover other types of cancer in the coming years.
Cancer just lost its most powerful weapon: Invisibility.
This week marks the official end of guesswork medicine. We are moving from reactive oncology to precise biological execution.
The data the world is ignoring:
Pancreatic Cancer is no longer silent. AI-driven multiomic… pic.twitter.com/LTYe8cAgsV
— Federico Lix Klett (@FedericoLKG) February 9, 2026
For the latest updates, click here.
